My Bibliography

select

Lee YS, Klomp JE, Stalnecker CA, Goodwin CM, Gao Y, Droby GN, Vaziri C, Bryant KL, Der CJ, Cox AD. VCP/p97, a pleiotropic protein regulator of the DNA damage response and proteostasis, is a potential therapeutic target in KRAS-mutant pancreatic cancer. Genes Cancer. 2023;14:30-49. doi: 10.18632/genesandcancer.231. eCollection 2023. PubMed PMID: 36923647; PubMed Central PMCID: PMC10010283.

select

Chang WH, Liu Y, Hammes EA, Bryant KL, Cerione RA, Antonyak MA. Oncogenic RAS promotes MYC protein stability by upregulating the expression of the inhibitor of apoptosis protein family member Survivin. J Biol Chem. 2023 Feb;299(2):102842. doi: 10.1016/j.jbc.2022.102842. Epub 2022 Dec 26. PubMed PMID: 36581205; PubMed Central PMCID: PMC9860443.

select

Goodwin CM, Waters AM, Klomp JE, Javaid S, Bryant KL, Stalnecker CA, Drizyte-Miller K, Papke B, Yang R, Amparo AM, Ozkan-Dagliyan I, Baldelli E, Calvert V, Pierobon M, Sorrentino JA, Beelen AP, Bublitz N, Lüthen M, Wood KC, Petricoin EF, Sers C, McRee AJ, Cox AD, Der CJ. Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer. Cancer Res. 2023 Jan 4;83(1):141-157. doi: 10.1158/0008-5472.CAN-22-0391. PubMed PMID: 36346366; PubMed Central PMCID: PMC9812941.

select

Stalnecker CA, Coleman MF, Bryant KL. Susceptibility to autophagy inhibition is enhanced by dual IGF1R and MAPK/ERK inhibition in pancreatic cancer. Autophagy. 2022 Jul;18(7):1737-1739. doi: 10.1080/15548627.2022.2042782. Epub 2022 Feb 24. PubMed PMID: 35201948; PubMed Central PMCID: PMC9298440.

select

Stalnecker CA, Grover KR, Edwards AC, Coleman MF, Yang R, DeLiberty JM, Papke B, Goodwin CM, Pierobon M, Petricoin EF, Gautam P, Wennerberg K, Cox AD, Der CJ, Hursting SD, Bryant KL. Concurrent Inhibition of IGF1R and ERK Increases Pancreatic Cancer Sensitivity to Autophagy Inhibitors. Cancer Res. 2022 Feb 15;82(4):586-598. doi: 10.1158/0008-5472.CAN-21-1443. PubMed PMID: 34921013; PubMed Central PMCID: PMC8886214.

select

DeLiberty JM, Robb R, Gates CE, Bryant KL. Unraveling and targeting RAS-driven metabolic signaling for therapeutic gain. Adv Cancer Res. 2022;153:267-304. doi: 10.1016/bs.acr.2021.07.010. Epub 2021 Aug 26. Review. PubMed PMID: 35101233.

select

Klomp JE, Lee YS, Goodwin CM, Papke B, Klomp JA, Waters AM, Stalnecker CA, DeLiberty JM, Drizyte-Miller K, Yang R, Diehl JN, Yin HH, Pierobon M, Baldelli E, Ryan MB, Li S, Peterson J, Smith AR, Neal JT, McCormick AK, Kuo CJ, Counter CM, Petricoin EF 3rd, Cox AD, Bryant KL, Der CJ. CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. Cell Rep. 2021 Nov 30;37(9):110060. doi: 10.1016/j.celrep.2021.110060. PubMed PMID: 34852220; PubMed Central PMCID: PMC8665414.

select

Chang WH, Nguyen TT, Hsu CH, Bryant KL, Kim HJ, Ying H, Erickson JW, Der CJ, Cerione RA, Antonyak MA. KRAS-dependent cancer cells promote survival by producing exosomes enriched in Survivin. Cancer Lett. 2021 Oct 1;517:66-77. doi: 10.1016/j.canlet.2021.05.031. Epub 2021 Jun 8. PubMed PMID: 34111513; PubMed Central PMCID: PMC8324551.

select

Tew BY, Durand JK, Bryant KL, Hayes TK, Peng S, Tran NL, Gooden GC, Buckley DN, Der CJ, Baldwin AS, Salhia B. Genome-wide DNA methylation analysis of KRAS mutant cell lines. Sci Rep. 2020 Jun 23;10(1):10149. doi: 10.1038/s41598-020-66797-x. PubMed PMID: 32576853; PubMed Central PMCID: PMC7311523.

select

Bryant KL, Stalnecker CA, Zeitouni D, Klomp JE, Peng S, Tikunov AP, Gunda V, Pierobon M, Waters AM, George SD, Tomar G, Papke B, Hobbs GA, Yan L, Hayes TK, Diehl JN, Goode GD, Chaika NV, Wang Y, Zhang GF, Witkiewicz AK, Knudsen ES, Petricoin EF 3rd, Singh PK, Macdonald JM, Tran NL, Lyssiotis CA, Ying H, Kimmelman AC, Cox AD, Der CJ. Author Correction: Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Nat Med. 2020 Jun;26(6):982. doi: 10.1038/s41591-020-0947-8. PubMed PMID: 32483362.

select

Hobbs GA, Baker NM, Miermont AM, Thurman RD, Pierobon M, Tran TH, Anderson AO, Waters AM, Diehl JN, Papke B, Hodge RG, Klomp JE, Goodwin CM, DeLiberty JM, Wang J, Ng RWS, Gautam P, Bryant KL, Esposito D, Campbell SL, Petricoin EF 3rd, Simanshu DK, Aguirre AJ, Wolpin BM, Wennerberg K, Rudloff U, Cox AD, Der CJ. Atypical KRAS(G12R) Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer. Cancer Discov. 2020 Jan;10(1):104-123. doi: 10.1158/2159-8290.CD-19-1006. Epub 2019 Oct 24. PubMed PMID: 31649109; PubMed Central PMCID: PMC6954322.

select

Parasido E, Avetian GS, Naeem A, Graham G, Pishvaian M, Glasgow E, Mudambi S, Lee Y, Ihemelandu C, Choudhry M, Peran I, Banerjee PP, Avantaggiati ML, Bryant K, Baldelli E, Pierobon M, Liotta L, Petricoin E, Fricke ST, Sebastian A, Cozzitorto J, Loots GG, Kumar D, Byers S, Londin E, DiFeo A, Narla G, Winter J, Brody JR, Rodriguez O, Albanese C. The Sustained Induction of c-MYC Drives Nab-Paclitaxel Resistance in Primary Pancreatic Ductal Carcinoma Cells. Mol Cancer Res. 2019 Sep;17(9):1815-1827. doi: 10.1158/1541-7786.MCR-19-0191. Epub 2019 Jun 4. PubMed PMID: 31164413; PubMed Central PMCID: PMC6726538.

select

Bryant KL, Der CJ. Blocking autophagy to starve pancreatic cancer. Nat Rev Mol Cell Biol. 2019 May;20(5):265. doi: 10.1038/s41580-019-0120-8. PubMed PMID: 30914805.

select

Bryant KL, Stalnecker CA, Zeitouni D, Klomp JE, Peng S, Tikunov AP, Gunda V, Pierobon M, Waters AM, George SD, Tomar G, Papke B, Hobbs GA, Yan L, Hayes TK, Diehl JN, Goode GD, Chaika NV, Wang Y, Zhang GF, Witkiewicz AK, Knudsen ES, Petricoin EF 3rd, Singh PK, Macdonald JM, Tran NL, Lyssiotis CA, Ying H, Kimmelman AC, Cox AD, Der CJ. Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Nat Med. 2019 Apr;25(4):628-640. doi: 10.1038/s41591-019-0368-8. Epub 2019 Mar 4. PubMed PMID: 30833752; PubMed Central PMCID: PMC6484853.

select

Vaseva AV, Blake DR, Gilbert TSK, Ng S, Hostetter G, Azam SH, Ozkan-Dagliyan I, Gautam P, Bryant KL, Pearce KH, Herring LE, Han H, Graves LM, Witkiewicz AK, Knudsen ES, Pecot CV, Rashid N, Houghton PJ, Wennerberg K, Cox AD, Der CJ. KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism. Cancer Cell. 2018 Nov 12;34(5):807-822.e7. doi: 10.1016/j.ccell.2018.10.001. PubMed PMID: 30423298; PubMed Central PMCID: PMC6321749.

select

Bryant KL, Der CJ. Mutant RAS Calms Stressed-Out Cancer Cells. Dev Cell. 2017 Jan 23;40(2):120-122. doi: 10.1016/j.devcel.2017.01.005. PubMed PMID: 28118599; PubMed Central PMCID: PMC6484846.

select

Zeitouni D, Pylayeva-Gupta Y, Der CJ, Bryant KL. KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment. Cancers (Basel). 2016 Apr 18;8(4). doi: 10.3390/cancers8040045. Review. PubMed PMID: 27096871; PubMed Central PMCID: PMC4846854.

select

Hayes TK, Neel NF, Hu C, Gautam P, Chenard M, Long B, Aziz M, Kassner M, Bryant KL, Pierobon M, Marayati R, Kher S, George SD, Xu M, Wang-Gillam A, Samatar AA, Maitra A, Wennerberg K, Petricoin EF 3rd, Yin HH, Nelkin B, Cox AD, Yeh JJ, Der CJ. Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression. Cancer Cell. 2016 Jan 11;29(1):75-89. doi: 10.1016/j.ccell.2015.11.011. Epub 2015 Dec 24. PubMed PMID: 26725216; PubMed Central PMCID: PMC4816652.

select

Bryant KL, Baird B, Holowka D. A novel fluorescence-based biosynthetic trafficking method provides pharmacologic evidence that PI4-kinase IIIα is important for protein trafficking from the endoplasmic reticulum to the plasma membrane. BMC Cell Biol. 2015 Feb 27;16:5. doi: 10.1186/s12860-015-0049-5. PubMed PMID: 25886792; PubMed Central PMCID: PMC4355129.

select

Singhai A, Wakefield DL, Bryant KL, Hammes SR, Holowka D, Baird B. Spatially defined EGF receptor activation reveals an F-actin-dependent phospho-Erk signaling complex. Biophys J. 2014 Dec 2;107(11):2639-51. doi: 10.1016/j.bpj.2014.09.048. Epub 2014 Dec 2. PubMed PMID: 25468343; PubMed Central PMCID: PMC4255200.

select

Holowka D, Korzeniowski MK, Bryant KL, Baird B. Polyunsaturated fatty acids inhibit stimulated coupling between the ER Ca(2+) sensor STIM1 and the Ca(2+) channel protein Orai1 in a process that correlates with inhibition of stimulated STIM1 oligomerization. Biochim Biophys Acta. 2014 Aug;1841(8):1210-6. doi: 10.1016/j.bbalip.2014.04.006. Epub 2014 Apr 24. PubMed PMID: 24769339; PubMed Central PMCID: PMC4069244.

select

Bryant KL, Mancias JD, Kimmelman AC, Der CJ. KRAS: feeding pancreatic cancer proliferation. Trends Biochem Sci. 2014 Feb;39(2):91-100. doi: 10.1016/j.tibs.2013.12.004. Epub 2014 Jan 2. Review. PubMed PMID: 24388967; PubMed Central PMCID: PMC3955735.

select

Bryant KL, Antonyak MA, Cerione RA, Baird B, Holowka D. Mutations in the polybasic juxtamembrane sequence of both plasma membrane- and endoplasmic reticulum-localized epidermal growth factor receptors confer ligand-independent cell transformation. J Biol Chem. 2013 Nov 29;288(48):34930-42. doi: 10.1074/jbc.M113.513333. Epub 2013 Oct 18. PubMed PMID: 24142702; PubMed Central PMCID: PMC3843104.

select

Antonyak MA, Li B, Boroughs LK, Johnson JL, Druso JE, Bryant KL, Holowka DA, Cerione RA. Cancer cell-derived microvesicles induce transformation by transferring tissue transglutaminase and fibronectin to recipient cells. Proc Natl Acad Sci U S A. 2011 Mar 22;108(12):4852-7. doi: 10.1073/pnas.1017667108. Epub 2011 Feb 28. PubMed PMID: 21368175; PubMed Central PMCID: PMC3064359.

select

Elzer KL, Heitzman DA, Chernin MI, Novak JF. Differential effects of serine proteases on the migration of normal and tumor cells: implications for tumor microenvironment. Integr Cancer Ther. 2008 Dec;7(4):282-94. doi: 10.1177/1534735408327250. PubMed PMID: 19116224.